PENTETATE ZINC TRISODIUM
LOE Approachingpentetate zinc trisodium
NDAINHALATION, INTRAVENOUSSOLUTIONPriority Review
Approved
Aug 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
PENTETATE ZINC TRISODIUM (pentetate zinc trisodium) is zn-dtpa forms stable chelates with metal ions by exchanging zinc for a metal of greater binding capacity. Approved for individuals with known, suspected internal contamination with plutonium, americium and 1 more indications. First approved in 2004.
Drug data last refreshed 12h ago · AI intelligence enriched 2mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Pentetate Zinc Trisodium (Zn-DTPA) is a chelating agent administered by inhalation or intravenous injection to treat internal radioactive contamination. It binds plutonium, americium, and curium ions and enhances their urinary elimination through stable chelate formation. This is a specialized radiological emergency and occupational health product with limited civilian use.
LOE Approaching
Product is in late-stage lifecycle with minimal commercial scale, indicating small, specialized team and limited growth opportunities in traditional brand roles.
Mechanism of Action
Zn-DTPA forms stable chelates with metal ions by exchanging zinc for a metal of greater binding capacity. The radioactive chelates are then excreted by glomerular filtration into the urine. In animal studies, Zn-DTPA forms less stable chelates with uranium and neptunium in vivo resulting in…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.